©The Author(s) 2016.
World J Gastroenterol. Mar 28, 2016; 22(12): 3471-3485
Published online Mar 28, 2016. doi: 10.3748/wjg.v22.i12.3471
Published online Mar 28, 2016. doi: 10.3748/wjg.v22.i12.3471
Table 3 Summary of changes in glycolysis in pancreatic ductal adenocarcinoma
| Glycolytic enzyme | Encoding gene | Change in PDAC | Implicated pathways | Known inhibitors | Inhibitor effect in PDAC |
| Hexokinase | HIF | 2-Deoxy-D-glucose | |||
| Hexokinase I | 10q22 | Up | mTor | ||
| Hexokinase II | 2p13 | Up | K-ras | 3-BP[21]; Lonidamine, Everolimus | Reduced PDAC survival/induces PDAC necrosis |
| Hexokinase III | 5q35.2 | - | Akt | ||
| Glucokinase | 7p15.3-p15.1 | ||||
| Phosphoglucose Isomerase (also known as Autocrine Motility Factor) | 19q13.1 | Up | HIF; Apoptosis | Insulin-like growth factor binding protein-3; Herceptin; 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole | Reduces overall cell viability and increases apoptosis rates |
| Phosphofructokinase | HIF | Aurintricarboxylic acid[191] | Inhibits fatty acid synthesis in rat hepatocytes | ||
| PFK-M (muscle type) | 12q13.3 | Down | |||
| PFK-L (liver type) | 21q22.3 | Up | |||
| PFK-P (platelet type) | 10p15.3-p15.2 | Up | |||
| Aldolase | HIF | 3-fluro-D-glucose; 4-fluro-D-glucose | |||
| Aldolase-A | 16p11.2 | Up | 3-[2-hydroxyethyl(methyl)amino]-2-quinoxalinecarbonitrile 1,4-dioxide | Reduces PDAC proliferation and tumour volume | |
| Aldolase-B | 5q22 | Down | |||
| Aldolase-C | 17cen-q12 | Up | |||
| Triose Phosphate Isomerase | 12p13 | Up | 2-phosphoglycolate; D-glycerol-1-phosphate[192] | ||
| Glyceraldehyde Phosphate Dehydrogenase | HIF; p53 | Iodoacetate[27]; gossypol[21] | Reduces cell survival and induces necrosis. No effect on K-ras | ||
| GAPDHS | 12p13 | Up | |||
| GAPDHS (testes-specific) | 19q13.12 | ||||
| Phosphoglycerate Kinase | HIF | 1,3-bisphosphoglycerate[193] | |||
| PGK1 | Xq13.3 | Up | |||
| PGK2 | 6p12.3 | ? | |||
| Phosphoglycerate Mutase | p53 | Inositol hexakisphosphate[194] | |||
| PGM-B | 1p31 | Up | |||
| PGM-M | 4p14 | Down | |||
| Enolase | c-Myc | Sodium fluoride[21]; D-tartonate; 3-aminoenolpyruvate 2-phosphate[195] | |||
| ENO1 (alpha) | 1p36.2 | Up | |||
| ENO2 (gamma, neuronal) | 12.p13 | Up | |||
| ENO3 (beta, muscle) | 17pter-p11 | - | |||
| Pyruvate Kinase | Tyrosine kinase | ||||
| Isoform PK-M1 (liver/RBC) | 1q21 | - | Akt/c-Myc | ||
| Isoform PK-M2 (muscle) | 15q22 | Up | L-phospholactate; M2-PK-binding peptide aptamers[196] | Anti-cancer effects in animal models | |
| Dimeric form | |||||
| Tetrameric form |
- Citation: Chan AK, Bruce JI, Siriwardena AK. Glucose metabolic phenotype of pancreatic cancer. World J Gastroenterol 2016; 22(12): 3471-3485
- URL: https://www.wjgnet.com/1007-9327/full/v22/i12/3471.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i12.3471